Related Experiment Video

Updated: Jun 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The effect of dyslipidemic drugs on mortality: A meta-analysis

Shuchi Jain1, Vikas Vaishnavi, Bhaswat S Chakraborty

  • 1Research and Development, Cadila Pharmaceuticals, Ahmadabad, Gujarat, India.

Indian Journal of Pharmacology
|February 24, 2010
PubMed

Insights

Dyslipidemic drugs significantly reduce the risk of dying from coronary artery disease, cardiovascular disease, and all causes. This meta-analysis confirms their effectiveness in preventing heart disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Previous meta-analyses focused primarily on statins, not all dyslipidemic drugs.
  • The impact of the broader class of dyslipidemic medications on mortality requires comprehensive evaluation.

Purpose of the Study:

  • To assess the overall effect of all dyslipidemic drugs on coronary artery disease (CAD) mortality, cardiovascular disease (CVD) mortality, and all-cause mortality.
  • To synthesize evidence from randomized controlled trials (RCTs) evaluating dyslipidemic drugs and mortality outcomes.

Main Methods:

  • A meta-analysis was conducted on 19 randomized placebo-controlled trials published before February 2006.
  • Included trials had a minimum duration of one year and reported on CAD mortality, CVD mortality, or all-cause mortality.
  • Data extraction included sample size, follow-up period, drug type, and clinical outcomes, with independent abstraction and consensus resolution for disagreements.

Main Results:

  • Dyslipidemic drugs demonstrated a significant risk reduction in CAD mortality (23%, P<0.00001).
  • A significant risk reduction was also observed for CVD mortality (19%, P<0.00001) and all-cause mortality (14%, P<0.0001).
  • The meta-analysis found no significant heterogeneity or inconsistency among the included trials.

Conclusions:

  • Dyslipidemic drugs are highly effective in reducing mortality from cardiovascular causes.
  • These medications provide significant benefits for both primary and secondary prevention of coronary artery disease.

Keywords:
All-cause mortalitycardio-vascular disease mortalitycoronary artery disease mortalitydyslipidemicmeta-analysis

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...